Pharma Journalist -

Otsuka Pharmaceutical and Visterra announce that they have entered into a definitive merger agreement pursuant to which Otsuka will acquire Visterra for approximately USD 430 million in…
Read More...

BioNTech AG and Genevant Sciences announced that they have entered into a collaboration to develop five mRNA therapeutic programs for rare diseases with high unmet medical need. The…
Read More...

CURE Pharmaceutical announced that it has signed a term sheet with Therapix Biosciences to acquire the non-pain assets of Therapix, subject to the completion of the related conditions.…
Read More...

AbbVie announced an update on a Phase 3 study (DBL3001) of ibrutinib (IMBRUVICA) in untreated (treatment-naïve) diffuse large B-cell lymphoma (DLBCL), an aggressive form of non-Hodgkin…
Read More...

Amphastar Pharmaceuticals announced business expansion plans for its subsidiary, Amphastar Nanjing Pharmaceuticals. To date, ANP has provided Active Pharmaceutical Ingredients and…
Read More...

Filament BioSolutions, a development-stage company focused on delivering innovative therapeutics for nutritional deficiencies, announced continued progress in the development of its…
Read More...

Catalent Pharma Solutions and Berkeley Lights announced Catalent Biologics will adopt BLI’s Beacon optofluidic platform to accelerate its cell line development workflow. The Beacon…
Read More...

Selexis SA announced that under the terms of an earlier commercial license agreement, Symphogen A/S has opened two investigational new drug applications (INDs) for clinical programs…
Read More...

SRI International announced a research agreement with Ionis Pharmaceuticals, combining SRI's proprietary FOX Three Molecular Guidance cellular targeting system (MGS) with Ionis'…
Read More...

BioCryst Pharmaceuticals announced that it has terminated the previously announced merger agreement with Idera Pharmaceuticals following the BioCryst stockholders’ failure to approve…
Read More...